You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Article Text

Article menu

Download PDFPDF

Correction
Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Free

http://dx.doi.org/10.1136/jitc-2021-003188corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Mandalá M, Larkin J, Ascierto PA, et al. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J ImmunoTher Cancer 2021;9:e003188. doi: 10.1136/jitc-2021-003188.

    This article has been corrected since it was first published. Author name has been corrected from 'Ivan Marquez' to 'Ivan Marquez-Rodas'.